Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

12.20
+0.58004.99%
Post-market: 12.200.00000.00%19:30 EDT
Volume:11.78K
Turnover:139.64K
Market Cap:62.26M
PE:-5.09
High:12.20
Open:11.64
Low:11.22
Close:11.62
52wk High:16.98
52wk Low:8.48
Shares:5.10M
Float Shares:2.07M
Volume Ratio:1.15
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3970
EPS(LYR):-2.9257
ROE:-1238.98%
ROA:-129.34%
PB:-4.44
PE(LYR):-4.17

Loading ...

MiNK Therapeutics Q2 Loss Narrows on Expense Discipline

Reuters
·
Aug 13

MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate

Benzinga Earnings
·
Aug 13

MiNK Therapeutics Q2 EPS USD -0.62

Reuters
·
Aug 13

Mink Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury

THOMSON REUTERS
·
Aug 13

Press Release: MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Dow Jones
·
Aug 13

Mink Therapeutics Inc Expected to Post a Loss of 60 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Mink Therapeutics - First Agent-797 Patients Alive and Afebrile at Day 28 with Improved Oxygenation

THOMSON REUTERS
·
Aug 07

Mink Therapeutics - no Major Serious Adverse Events Attributed to Agent-797 in First Patients

THOMSON REUTERS
·
Aug 07

Mink Therapeutics - Enrollment Continues in Lviv with U.S. Sites Opening; Additional Data Expected Early 2027

THOMSON REUTERS
·
Aug 07

MiNK Therapeutics Reports Early Phase 2 Data for agenT-797 in Severe Hypoxemic Pneumonia Trial

Reuters
·
Aug 07

Mink Therapeutics to Report Q2 Results, Host Conference Call and Webcast

Reuters
·
Aug 06

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

GlobeNewswire
·
Aug 06

MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch

TIPRANKS
·
Jun 27

MiNK Therapeutics Stockholders Back Directors, Ratify Auditor

TIPRANKS
·
Jun 23

Mink Therapeutics shareholders approve KPMG as auditor

Reuters
·
Jun 23

MiNK Therapeutics Rocked by Fresh Insider Share Sale

TIPRANKS
·
Jun 06

MiNK Therapeutics director Barbara Ryan disposes of 1,500 common shares worth $19,143.25

Reuters
·
Jun 06

MiNK Therapeutics announces virtual annual shareholders meeting

Reuters
·
Jun 04

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

GlobeNewswire
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's

Reuters
·
May 29